臨床泌尿器科65巻6号

2011年05月発行

特集 ED診療のコツ―私はこうしている

性腺機能低下を伴うED―診断と治療

著者： 佐藤嘉一¹

所属機関： ¹三樹会病院泌尿器科

ページ範囲：P.385 - P.391

文献概要

要旨　性腺機能低下を伴うED（electile dysfunction）症例の診断および治療につき述べる。テストステロン低下（testosterone deficiency：TD）は，勃起能，性欲の低下，射精の遅延などの性機能低下に直接的に関与する。さらにはメタボリックシンドローム（MetS）や心血管系疾患（CVD）への関連が注目されている。MetSやCVDはEDの主たるリスクファクターである。testosteroneは性機能への直接的作用のみならず，MetSやCVDを介し間接的に勃起能の低下に影響する可能性がある。TDを伴うED症例への治療として，testosterone補充とphosphodiesterase type 5阻害薬（PDE5-I）の併用療法も試みられている。

参考文献

1）Yassin AA and Saad F：Testosterone and erectile dysfunction. J Androl 29：593-604, 2008

2）Buvat J, Maggi M, Gooren L, et al：Endocrine aspects of male sexual dysfunctions. J Sex Med 7：1627-1656, 2010

3）Traish AM, Guay A, Feeley R, et al：The dark side of testosterone deficiency：Ⅰ. Metabolic syndrome and erectile dysfunction. J Androl 30：10-22, 2009

4）加齢男性性腺機能低下症候群診療の手引き．じほう，東京，2007

5）Morelli A, Corona G, Filippi S, et al：Which patients with sexual dysfunction are suitable for testosterone replacement therapy? J Endocrinol Invest 30：880-888, 2007

6）Sakamoto H：The neurobiology of psychogenic erectile dysfunction in the spinal cord. J Androl 31：519-526, 2010

7）Morelli A, Filippi S, Mancina R, et al：Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 145：2253-2263, 2004

8）Morales A and Lunenfeld B：Investigation, treatment and monitoring of late-onset hypogonadism in males official recommendations of ISSAM hormone replacement therapy in the aging male. Aging Male 5：74-86, 2002

9）Wang C, Nieschlag E, Swerdloff R, et al：Investigation, treatment and monitoring of late-onset hypogonadism in males：ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 159：507-514, 2008

10）Petak SM, Nankin HR, Spark RF, et al：American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients―2002 update. Endocr Pract 8：440-455, 2002

11）Wu FC, Tajar A, Beynon JM, et al（EMAS Group）：Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363：123-135, 2010

12）Traish AM, Saad F, Feeley RJ, et al：The dark side of testosterone deficiency：Ⅲ. Cardiovascular disease. J Androl 30：477-494, 2009

13）McGrath KC, McRobb LS and Heather AK：Androgen therapy and atherosclerotic cardiovascular disease. Vasc Health Risk Manag 4：11-21, 2008

14）Buvat J and Bou Jaoudé G：Significance of hypogonadism in erectile dysfunction. World J Urol 24：657-667, 2006

15）Leibowitz RL, Dorff TB, Tucker S, et al：Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int 105：1397-1401, 2010

16）Shabsigh R, Kaufman JM, Steidle C, et al：Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 179：（5 Suppl）：S97-S102, 2008

17）Buvat J, Montorsi F, Maggi M, et al：Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1％ hydroalcoholic testosterone gel in the treatment of erectile dysfunction（TADTEST study）. J Sex Med 8：284-293, 2011

18）Tsertsvadze A, Fink HA, Yazdi F, et al：Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction：a systematic review and meta-analysis. Ann Intern Med 151：650-661, 2009

19）Zitzmann M, Faber S and Nieschlag E：Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin EndocrinolMetab 91：4335-4343, 2006

20）Travison TG, Morley JE, Araujo AB, et al：The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab 91：2509-2513, 2006

21）Corona G, Jannini EA, Mannucci E, et al：Different testosterone levels are associated with ejaculatory dysfunction. J Sex Med 5：1991-1998, 2008